Drug Availability Update

Further to DrugAlert 506, HPS Pharmacies wish to give notice that Pfizer Australia is continuing to experience a supply interruption for heparin as follows:

DBL™ Heparin Sodium Injection BP
Heparin sodium 5,000 IU/0.2mL
ARTG 16349

 DBL™ Heparin Sodium Injection BP
Heparin sodium 5,000 IU/1mL
ARTG 12881

This supply interruption is due to an internal supply chain delay at Pfizer. There are no safety concerns with the above products. Supplies of each product are expected to return to normal in mid-January 2020.

The following heparin sodium presentations are currently unaffected by this supply interruption:

  • Heparin sodium 5,000 IU/5mL
  • Heparin sodium 25,000 IU/5mL
  • Heparin sodium 35,000 IU/35mL

Therapeutic alternatives such as low molecular weight heparins may be considered, where appropriate.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer Australia on 1800 629 921 or your pharmacist at HPS Pharmacies.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates